Adverse pharmacokinetic interactions between illicit substances and clinical drugs

References

• Abbott KL, Chaudhury CS, Chandran A, Vishveshwara S, Dvorak Z, Jiskrova E, Poulikova K, Vyhlidalova B, Mani S, Pondugula S R. 2019. Belinostat, at its clinically relevant concentrations, inhibits rifampicin-induced CYP3A4 and MDR1 gene expression. Mol Pharmacol. 95(3):324–334.
   PubMed Web of Science ®Google Scholar
• Abebe W. 2018. Khat: a substance of growing abuse with adverse drug interaction risks. J Natl Med Assoc. 110(6):624–634.
   PubMed Web of Science ®Google Scholar
• Alfaifi H, Abdelwahab SI, Mohan S. 2017. Catha edulis Forsk. (Khat): evaluation of its antidepressant-like activity. Phcog Mag. 13(Suppl 2):S354–S358.
   Google Scholar
• AlRabiah H, Ahad A, Mostafa GAE, Al-Jenoobi FI. 2018. Effect of naltrexone hydrochloride on cytochrome P450 1A2, 2C9, 2D6, and 3A4 activity in human liver microsomes. Eur J Drug Metab Pharmacokinet. 43(6):707–713.
   PubMed Web of Science ®Google Scholar
• Amoroso T, Workman M. 2016. Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: a preliminary meta-analysis and comparison to prolonged exposure therapy. J Psychopharmacol. 30(7):595–600.
   PubMed Web of Science ®Google Scholar
• Antolino-Lobo I, Meulenbelt J, Nijmeijer SM, Maas-Bakker RF, Meijerman I, van den Berg M, van Duursen MBM. 2011. 3,4-methylenedioxymethamphetamine (MDMA) interacts with therapeutic drugs on CYP3A by inhibition of pregnane X receptor (PXR) activation and catalytic enzyme inhibition. Toxicol Lett. 203(1):82–91.
   PubMed Web of Science ®Google Scholar
• Araujo P, Carvalho MG, van Weelden M. 2016. Substance misuse and sexual function in adolescents with chronic diseases. Rev Paul Pediatr. 34(3):323–329.
   PubMedGoogle Scholar
• Baker JR, Jatlow P, McCance-Katz EF. 2007. Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend. 87(2-3):202–209.
   PubMed Web of Science ®Google Scholar
• Baltes BB. 2001. International encyclopedia of the social and behavioral sciences. New York (NY): Elsevier (Pergamon).
   Google Scholar
• Barker SN. 2018. N, N-Dimethyltryptamine (DMT), an endogenous hallucinogen: past, present, and future research to determine its role and function. Front Neurosci. 12:536.
   PubMed Web of Science ®Google Scholar
• Barton MK. 2011. Drug interactions in cancer patients receiving antidepressants are common, researchers report. CA Cancer J Clin. 61(5):283–284.
   PubMed Web of Science ®Google Scholar
• Beckett RD, Stump CD, Dyer MA. 2019. Evaluation of drug information resources for drug-ethanol and drug-tobacco interactions. J Med Libr Assoc. 107(1):62–71.
   PubMed Web of Science ®Google Scholar
• Bedada W, de Andrés F, Engidawork E, Pohanka A, Beck O, Bertilsson L, Llerena A, Aklillu E. 2015. The Psychostimulant Khat (Catha edulis) inhibits CYP2D6 enzyme activity in humans. J Clin Psychopharmacol. 35(6):694–699.
   PubMed Web of Science ®Google Scholar
• Bedi G, Cooper ZD, Haney M. 2013. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol. 18(5):872–881.
   PubMed Web of Science ®Google Scholar
• Bertron JL, Seto M, Lindsley CW. 2018. DARK classics in chemical neuroscience: phencyclidine (PCP). ACS Chem Neurosci. 9(10):2459–2474.
   PubMed Web of Science ®Google Scholar
• Bey T, Patel A. 2007. Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug. Cal J Emerg Med. 8(1):9–14.
   PubMedGoogle Scholar
• Bonson KR, Murphy DL. 1995. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res. 73(1–2):229–233.
   Web of Science ®Google Scholar
• Borgelt LM, Franson KL, Nussbaum AM, Wang GS. 2013. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 33(2):195–209.
   PubMed Web of Science ®Google Scholar
• Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. 2008. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. 103(6):1048–1050.
   PubMed Web of Science ®Google Scholar
• Braida D, Capurro V, Zani A, Rubino T, Viganò D, Parolaro D, Sala M. 2009. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol. 157(5):844–853.
   PubMed Web of Science ®Google Scholar
• Broseus J, Gentile N, Esseiva P. 2016. The cutting of cocaine and heroin: A critical review. Forensic Sci Int. 262:73–83.
   PubMed Web of Science ®Google Scholar
• Butelman ER, Caspers M, Lovell KM, Kreek MJ, Prisinzano TE. 2012. Behavioral effects and central nervous system levels of the broadly available kappa-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo. J Pharmacol Exp Ther. 341(3):802–808.
   PubMed Web of Science ®Google Scholar
• Byock I. 2018. Taking psychedelics seriously. J Palliat Med. 21(4):417–421.
   PubMed Web of Science ®Google Scholar
• Callaway JC, Grob CS. 1998. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoactive Drugs. 30(4):367–369.
   PubMed Web of Science ®Google Scholar
• Cameron K, Kolanos R, Verkariya R, De Felice L, Glennon RA. 2013. Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of “bath salts,” produce opposite effects at the human dopamine transporter. Psychopharmacology (Berl). 227(3):493–499.
   PubMed Web of Science ®Google Scholar
• Cameron LP, Olson DE. 2018. Dark classics in chemical neuroscience: N, N-dimethyltryptamine (DMT). ACS Chem Neurosci. 9(10):2344–2357.
   PubMed Web of Science ®Google Scholar
• Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. 2012. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol. 83(8):1112–1126.
   PubMed Web of Science ®Google Scholar
• Chhatre S, Metzger DS, Malkowicz SB, Woody G, Jayadevappa R. 2014. Substance use disorder and its effects on outcomes in men with advanced-stage prostate cancer. Cancer. 120(21):3338–3345.
   PubMed Web of Science ®Google Scholar
• Choi JH, Ko CM. 2017. Food and drug interactions. J Lifestyle Med. 7(1):1–9.
   PubMedGoogle Scholar
• Climko RP, Roehrich H, Sweeney DR, Al-Razi J. 1987. Ecstacy: a review of MDMA and MDA. Int J Psychiatry Med. 16(4):359–372.
   Web of Science ®Google Scholar
• Cochin J, Woods LA, Seevers MH. 1951. The absorption, distribution and urinary excretion of mescaline in the dog. J Pharmacol Exp Ther. 101(2):205–209.
   PubMed Web of Science ®Google Scholar
• Coe MA, Jufer Phipps RA, Cone EJ, Walsh SL. 2018. Bioavailability and pharmacokinetics of oral cocaine in humans. J Anal Toxicol. 42(5):285–292.
   PubMed Web of Science ®Google Scholar
• Coffman BL, King CD, Rios GR, Tephly TR. 1998. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos. 26(1):73–77.
   PubMed Web of Science ®Google Scholar
• Colfax G, Guzman R. 2006. Club drugs and HIV infection: a review. Clin Infect Dis. 42(10):1463–1469.
   PubMed Web of Science ®Google Scholar
• Cooper ZD, Haney M. 2010. Opioid antagonism enhances marijuana’s effects in heavy marijuana smokers. Psychopharmacology (Berl). 211(2):141–148.
   PubMed Web of Science ®Google Scholar
• Cruz A, Domingos S, Gallardo E, Martinho A. 2017. A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics. Phytochemistry. 137:9–14.
   PubMed Web of Science ®Google Scholar
• De La Garza R, Galloway GP, Newton TF, Mendelson J, Haile CN, Dib E, Hawkins RY, Chen C-YA, Mahoney JJ, Mojsiak J, et al. 2014. Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine. Prog Neuropsychopharmacol Biol Psychiatry. 50:44–52.
   PubMed Web of Science ®Google Scholar
• de la Torre R, Yubero-Lahoz S, Pardo-Lozano R. 2012. MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? Front Genet. 3:235.
   PubMedGoogle Scholar
• de Leon J, Nikoloff DM. 2008. Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports. CNS Spectr. 13(2):133–135.
   PubMed Web of Science ®Google Scholar
• Delaforge M, Jaouen M, Bouille G. 1999. Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D. Environ Toxicol Pharmacol. 7(3):153–158.
   PubMed Web of Science ®Google Scholar
• DeVane CL, Nemeroff CB. 2001. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 40(7):509–522.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. 2017. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev. 49(1):84–91.
   PubMed Web of Science ®Google Scholar
• Dominguez-Clave E, Soler J, Elices M, Pascual JC, Álvarez E, de la Fuente Revenga M, Friedlander P, Feilding A, Riba J. 2016. Ayahuasca: pharmacology, neuroscience and therapeutic potential. Brain Res Bull. 126(Pt 1):89–101.
   PubMed Web of Science ®Google Scholar
• Dominici P, Kopec K, Manur R, Khalid A, Damiron K, Rowden A. 2015. Phencyclidine intoxication case series study. J Med Toxicol. 11(3):321–325.
   PubMed Web of Science ®Google Scholar
• Doring B, Petzinger E. 2014. Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism. Drug Metab Rev. 46(3):261–282.
   PubMed Web of Science ®Google Scholar
• Dumbreck S, Flynn A, Nairn M, Wilson M, Treweek S, Mercer SW, Alderson P, Thompson A, Payne K, Guthrie B, et al. 2015. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ. 350(mar11 2):h949.
   PubMed Web of Science ®Google Scholar
• Edwards IR, Aronson JK. 2000. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 356(9237):1255–1259.
   PubMed Web of Science ®Google Scholar
• Ernst FR, Grizzle AJ. 2001. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 41(2):192–199.
   PubMedGoogle Scholar
• Fallon MT, Albert Lux E, McQuade R, Rossetti S, Sanchez R, Sun W, Wright S, Lichtman AH, Kornyeyeva E. 2017. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain. 11(3):119–133.
   PubMed Web of Science ®Google Scholar
• Fang J, Yu PH, Boulton AA, Gorrod JW. 1995. Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia. Psychopharmacology (Berl). 118(2):206–212.
   PubMed Web of Science ®Google Scholar
• Farre M, Abanades S, Roset PN, Peiró AM, Torrens M, O’Mathúna B, Segura M, de la Torre R. 2007. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther. 323(3):954–962.
   PubMed Web of Science ®Google Scholar
• FDA 2018. Epidiolex - FDA.
   Google Scholar
• Flannery PC, Abbott KL, Pondugula SR. 2019. Correlation of PPM1A downregulation with CYP3A4 repression in the tumor liver tissue of hepatocellular carcinoma patients. Eur J Drug Metab Pharmacokinet. DOI:10.1007/s13318-019-00595-3.
   PubMed Web of Science ®Google Scholar
• Fletcher PJ, Sinyard J, Salsali M, Baker GB. 2004. Fluoxetine, but not sertraline or citalopram, potentiates the locomotor stimulant effect of cocaine: possible pharmacokinetic effects. Psychopharmacology (Berl). 174(3):406–413.
   PubMed Web of Science ®Google Scholar
• Flockhart DA, Tanus-Santos JE. 2002. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 162(4):405–412.
   PubMed Web of Science ®Google Scholar
• Fluyau D, Revadigar N. 2017. Biochemical benefits, diagnosis, and clinical risks evaluation of kratom. Front Psychiatry. 8:62.
   PubMed Web of Science ®Google Scholar
• Fraser DJ, Zumsteg A, Meyer UA. 2003. Nuclear receptors constitutive androstane receptor and pregnane X receptor activate a drug-responsive enhancer of the murine 5-aminolevulinic acid synthase gene. J Biol Chem. 278(41):39392–39401.
   PubMed Web of Science ®Google Scholar
• Geffrey AL, Pollack SF, Bruno PL, Thiele EA. 2015. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 56(8):1246–1251.
   PubMed Web of Science ®Google Scholar
• Geiger HA, Wurst MG, Daniels RN. 2018. DARK classics in chemical neuroscience: psilocybin. ACS Chem Neurosci. 9(10):2438–2447.
   PubMed Web of Science ®Google Scholar
• Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K. 1995. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 57(6):670–677.
   PubMed Web of Science ®Google Scholar
• Grayson L, Vines B, Nichol K, Szaflarski JP. 2018. An interaction between warfarin and cannabidiol, a case report. Epilepsy Behav Case Rep. 9:10–11.
   PubMed Web of Science ®Google Scholar
• Hales G, Roth N, Smith D. 2000. Possible fatal interaction between protease inhibitors and methamphetamine. Antivir Ther. 5(1):19.
   PubMed Web of Science ®Google Scholar
• Hara Y, Nakajima M, Miyamoto K-I, Yokoi T. 2007. Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are coadministered with morphine. Drug Metab Pharmacokinet. 22(2):103–112.
   PubMed Web of Science ®Google Scholar
• Harmsen S, Meijerman I, Beijnen JH, Schellens JHM. 2007. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev. 33(4):369–380.
   PubMed Web of Science ®Google Scholar
• Harrington RD, Woodward JA, Hooton TM, Horn JR. 1999. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med. 159(18):2221–2224.
   PubMed Web of Science ®Google Scholar
• Henry JA, Hill IR. 1998. Fatal interaction between ritonavir and MDMA. Lancet. 352(9142):1751–1752.
   PubMed Web of Science ®Google Scholar
• Hilton T. 2007. Pharmacological issues in the management of people with mental illness and problems with alcohol and illicit drug misuse. Crim Behav Ment Health. 17(4):215–224.
   PubMedGoogle Scholar
• Holler JM, Vorce SP, McDonough-Bender PC, Magluilo J, Solomon CJ, Levine B. 2011. A drug toxicity death involving propylhexedrine and mitragynine. J Anal Toxicol. 35(1):54–59.
   PubMed Web of Science ®Google Scholar
• Hsu WY, Chiu NY, Liao YC. 2009. Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy. Acta Psychiatr Scand. 120(1):76–79.
   PubMed Web of Science ®Google Scholar
• Huang SM, Lesko LJ. 2004. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J Clin Pharmacol. 44(6):559–569.
   PubMed Web of Science ®Google Scholar
• Huecker MR, Marraffa J. 2019. Heroin. Treasure Island (FL): StatPearls.
   Google Scholar
• Huestis MA. 2007. Human cannabinoid pharmacokinetics. C&B. 4(8):1770–1804.
   Web of Science ®Google Scholar
• Hughes RL. 2019. Fatal combination of mitragynine and quetiapine - a case report with discussion of a potential herb-drug interaction. Forensic Sci Med Pathol. 15:110–113.
   PubMed Web of Science ®Google Scholar
• Hunt DE, Kling R, Almozlino Y, Jalbert S, Chapman MT, Rhodes W. 2015. Telling the truth about drug use: how much does it matter? J Drug Issues. 45(3):314–329.
   Web of Science ®Google Scholar
• Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME. 2011. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. Clin Pharmacol Ther. 90(2):246–255.
   PubMed Web of Science ®Google Scholar
• Hysek CM, Simmler LD, Nicola VG, Vischer N, Donzelli M, Krähenbühl S, Grouzmann E, Huwyler J, Hoener MC, Liechti ME, et al. 2012. Duloxetine inhibits effects of MDMA (“ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One. 7(5):e36476.
   PubMed Web of Science ®Google Scholar
• Hysek CM, Simmler LD, Schillinger N, Meyer N, Schmid Y, Donzelli M, Grouzmann E, Liechti ME. 2014. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Int J Neuropsychopharm. 17(03):371–381.
   PubMed Web of Science ®Google Scholar
• Iffland K, Grotenhermen F. 2017. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2(1):139–154.
   PubMedGoogle Scholar
• Iyer SV, Harpaz R, LePendu P, Bauer-Mehren A, Shah NH. 2014. Mining clinical text for signals of adverse drug-drug interactions [Research Support, N.I.H., Extramural]. J Am Med Inform Assoc. 21(2):353–362.
   PubMed Web of Science ®Google Scholar
• Izzo AA. 2012. Interactions between herbs and conventional drugs: overview of the clinical data [Review]. Med Princ Pract. 21(5):404–428.
   PubMed Web of Science ®Google Scholar
• Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148(10):1301–1308.
   PubMed Web of Science ®Google Scholar
• Jiang X-L, Shen H-W, Mager DE, Yu A-M. 2013. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status. Drug Metab Dispos. 41(5):975–986.
   PubMed Web of Science ®Google Scholar
• Johnson B, Wells L, Roache J, Wallace C, Aitdaoud N, Wang Y. 2005. Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: results from two human laboratory studies. Am J Hypertens. 18(6):813–822.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Griffiths RR. 2017. Potential therapeutic effects of psilocybin. Neurotherapeutics. 14(3):734–740.
   PubMed Web of Science ®Google Scholar
• Jushchyshyn MI, Kent UM, Hollenberg PF. 2003. The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine. Drug Metab Dispos. 31(1):46–52.
   PubMed Web of Science ®Google Scholar
• Jusko WJ, Gardner MJ, Mangione A, Schentag JJ, Koup JR, Vance JW. 1979. Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci. 68(11):1358–1366.
   PubMed Web of Science ®Google Scholar
• Kamendulis LM, Brzezinski MR, Pindel EV, Bosron WF, Dean RA. 1996. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther. 279(2):713–717.
   PubMed Web of Science ®Google Scholar
• Karch SB. 1998. Diphenhydramine toxicity: comparisons of postmortem findings in diphenhydramine-, cocaine-, and heroin-related deaths. Am J Forensic Med Pathol. 19(2):143–147.
   PubMed Web of Science ®Google Scholar
• Kaushal N, Matsumoto RR. 2011. Role of sigma receptors in methamphetamine-induced neurotoxicity. CN. 9(1):54–57.
   Web of Science ®Google Scholar
• Kesha K, Boggs CL, Ripple MG, Allan CH, Levine B, Jufer-Phipps R, Doyon S, Chi P, Fowler DR. 2013. Methylenedioxypyrovalerone (“bath salts”), related death: case report and review of the literature. J Forensic Sci. 58(6):1654–1659.
   PubMed Web of Science ®Google Scholar
• Kim TW, Samet JH, Cheng DM, Bernstein J, Wang N, German J, Saitz R. 2015. The spectrum of unhealthy drug use and quality of care for hypertension and diabetes: a longitudinal cohort study. BMJ Open. 5(12):e008508.
   PubMed Web of Science ®Google Scholar
• Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA. 2008. Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit. 30(3):320–332.
   PubMed Web of Science ®Google Scholar
• Kong TY, Kim J-H, Kim DK, Lee HS. 2018. Synthetic cannabinoids are substrates and inhibitors of multiple drug-metabolizing enzymes. Arch Pharm Res. 41(7):691–710.
   PubMed Web of Science ®Google Scholar
• Kong WM, Chik Z, Ramachandra M, Subramaniam U, Aziddin RER, Mohamed Z. 2011. Evaluation of the effects of Mitragyna speciosa alkaloid extract on cytochrome P450 enzymes using a high throughput assay. Molecules. 16(9):7344–7356.
   PubMed Web of Science ®Google Scholar
• Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, Abrams DI. 2002. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS. 16(4):543–550.
   PubMed Web of Science ®Google Scholar
• Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, Adson DE. 2005. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol. 25(3):226–229.
   PubMed Web of Science ®Google Scholar
• Kudlacek O, Hofmaier T, Luf A, Mayer FP, Stockner T, Nagy C, Holy M, Freissmuth M, Schmid R, Sitte HH, et al. 2017. Cocaine adulteration. J Chem Neuroanat. 83–84:75–81.
   PubMed Web of Science ®Google Scholar
• Kudo S, Ishizaki T. 1999. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 37(6):435–456.
   PubMed Web of Science ®Google Scholar
• Kuhn M, Campillos M, González P, Jensen LJ, Bork P. 2008. Large-scale prediction of drug-target relationships. FEBS Lett. 582(8):1283–1290.
   PubMed Web of Science ®Google Scholar
• Kumar S, Rao PSS, Earla R, Kumar A. 2015. Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert Opin Drug Metab Toxicol. 11(3):343–355.
   PubMed Web of Science ®Google Scholar
• Kurogi K, Chepak A, Hanrahan MT, Liu M-Y, Sakakibara Y, Suiko M, Liu M-C. 2014. Sulfation of opioid drugs by human cytosolic sulfotransferases: metabolic labeling study and enzymatic analysis. Eur J Pharm Sci. 62:40–48.
   PubMed Web of Science ®Google Scholar
• Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, Bedotto JB, Danziger RS, Hillis LD. 1990. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med. 112(12):897–903.
   PubMed Web of Science ®Google Scholar
• Laurenzana EM, Owens SM. 1997. Metabolism of phencyclidine by human liver microsomes. Drug Metab Dispos. 25(5):557–563.
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. 1998. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies [Meta-Analysis Research Support, Non-U.S. Gov’t]. JAMA. 279(15):1200–1205.
   PubMed Web of Science ®Google Scholar
• Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, Hebert L, Newhouse JP, Weiler PC, Hiatt H, et al. 1991. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II [Research Support, Non-U.S. Gov’t]. N Engl J Med. 324(6):377–384.
   PubMed Web of Science ®Google Scholar
• Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky IL, Klaassen CD, Gonzalez FJ, Ma X. 2013. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med. 19(4):418–420.
   PubMed Web of Science ®Google Scholar
• Liang W, Lenton S, Allsop S, Chikritzhs T. 2011. Does availability of illicit drugs mediate the association between mental illness and substance use? Subst Use Misuse. 46(10):1304–1308.
   PubMed Web of Science ®Google Scholar
• Libanio Osorio Marta RF. 2019. Metabolism of lysergic acid diethylamide (LSD): an update. Drug Metab Rev. 51(3):378–387.
   PubMed Web of Science ®Google Scholar
• Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, Wright S, Kornyeyeva E, Fallon MT. 2018. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage. 55(2):179–188 e1.
   PubMed Web of Science ®Google Scholar
• Lin LY, Di Stefano EW, Schmitz DA, Hsu L, Ellis SW, Lennard MS, Tucker GT, Cho AK. 1997. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos. 25(9):1059–1064.
   PubMed Web of Science ®Google Scholar
• Liveri K, Constantinou MA, Afxentiou M, Kanari P. 2016. A fatal intoxication related to MDPV and pentedrone combined with antipsychotic and antidepressant substances in Cyprus. Forensic Sci Int. 265:160–165.
   PubMed Web of Science ®Google Scholar
• Lobao-Soares B, Eduardo-da-Silva P, Amarilha H, Pinheiro-da-Silva J, Silva PF, Luchiari AC. 2018. It’s tea time: interference of Ayahuasca Brew on discriminative learning in Zebrafish. Front Behav Neurosci. 12:190.
   PubMed Web of Science ®Google Scholar
• Lopez P, Velez R, Rivera V, Rodriguez N, Yamamura Y. 2005. Characteristics of P-glycoprotein (Pgp) Upregulated in Chronic Cocaine Users and HIV Infected Persons. Retrovirology. 2(Suppl 1):P142.
   Web of Science ®Google Scholar
• Luethi D, Hoener MC, Krähenbühl S, Liechti ME, Duthaler U. 2019. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: implications for clinical LSD use. Biochem Pharmacol. 164:129–138.
   PubMed Web of Science ®Google Scholar
• Malaplate-Armand C, Ferrari L, Masson C, Visvikis-Siest S, Lambert H, Batt AM. 2005. Down-regulation of astroglial CYP2C, glucocorticoid receptor and constitutive androstane receptor genes in response to cocaine in human U373 MG astrocytoma cells. Toxicol Lett. 159(3):203–211.
   PubMed Web of Science ®Google Scholar
• Manda VK, Avula B, Dale OR, Ali Z, Khan IA, Walker LA, Khan SI. 2017. PXR mediated induction of CYP3A4, CYP1A2, and P-gp by Mitragyna speciosa and its alkaloids. Phytother Res. 31(12):1935–1945.
   PubMed Web of Science ®Google Scholar
• Manevski N, Kurkela M, Höglund C, Mauriala T, Court MH, Yli-Kauhaluoma J, Finel M. 2010. Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. Drug Metab Dispos. 38(3):386–395.
   PubMed Web of Science ®Google Scholar
• Mann H, Ladenheim B, Hirata H, Moran TH, Cadet JL. 1997. Differential toxic effects of methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) in multidrug-resistant (mdr1a) knockout mice. Brain Res. 769(2):340–346.
   PubMed Web of Science ®Google Scholar
• Markova J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C. 2019. Sativex((R)) as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int J Neurosci. 129(2):119–128.
   PubMed Web of Science ®Google Scholar
• Marona-Lewicka D, Thisted RA, Nichols DE. 2005. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology (Berl). 180(3):427–435.
   PubMed Web of Science ®Google Scholar
• Marquez B, Van Bambeke F. 2011. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. CDT. 12(5):600–620.
   Web of Science ®Google Scholar
• Matsunaga T, Iwawaki Y, Watanabe K, Yamamoto I, Kageyama T, Yoshimura H. 1995. Metabolism of delta 9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sci. 56(23–24):2089–2095.
   PubMed Web of Science ®Google Scholar
• Matthew BJ, Gedzior JS. 2015. Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate. Int J Psychiatry Med. 50(4):405–411.
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Kosten TR, Jatlow P. 1998. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend. 52(1):27–39.
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF. 2011. Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women. Life Sci. 88(21-22):953–958.
   PubMed Web of Science ®Google Scholar
• Meng Q, Liu K. 2015. Pharmacokinetic interactions between herbal medicines and prescribed drugs: focus on drug metabolic enzymes and transporters. CDM. 15(8):791–807.
   Google Scholar
• Miller GM. 2011. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem. 116(2):164–176.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Grob CS, Brewerton TD. 2016. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 3(5):481–488.
   PubMed Web of Science ®Google Scholar
• Molina DK, Hargrove VM. 2011. Fatal cocaine interactions: a review of cocaine-related deaths in Bexar County, Texas. Am J Forensic Med Pathol. 32(1):71–77.
   PubMed Web of Science ®Google Scholar
• Monte AP, Waldman SR, Marona-Lewicka D, Wainscott DB, Nelson DL, Sanders-Bush E, Nichols DE. 1997. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem. 40(19):2997–3008.
   PubMed Web of Science ®Google Scholar
• Nichols DE, Johnson MW, Nichols CD. 2017. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 101(2):209–219.
   PubMed Web of Science ®Google Scholar
• NIDA. 2018. Adulteration of drugs with toxic cutting agents: a rapidly developing global public health emergency 2018. Bethesda (MD): NIDA. https://www.drugabuse.gov/international/2018-nida-international-forum-building-international-collaborative-research-drug-abuse.
   Google Scholar
• NIDA. 2019. Commonly abused drugs charts 2018. Bethesda (MD): NIDA. https://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs-charts.
   Google Scholar
• NIDA. 2017. Trends and statistics 2017. Bethesda (MD): NIDA. https://www.drugabuse.gov/related-topics/trends-statistics.
   Google Scholar
• NIH. 2019. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/home.
   Google Scholar
• Nookala AR, Li J, Ande A, Wang L, Vaidya NK, Li W, Kumar S, Kumar A. 2016. Effect of methamphetamine on spectral binding, ligand docking and metabolism of anti-HIV drugs with CYP3A4. PLoS One. 11(1):e0146529.
   PubMed Web of Science ®Google Scholar
• Overton PG, Marrow LP, Brain PF, Clark D. 2000. Certain clinically-utilized antibiotics enhance the behavioural effects of cocaine. Addict Biol. 5(3):283–288.
   PubMed Web of Science ®Google Scholar
• Pal D, Kwatra D, Minocha M, Paturi DK, Budda B, Mitra AK. 2011. Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. Life Sci. 88(21–22):959–971.
   PubMed Web of Science ®Google Scholar
• Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, Mota-Rolim SA, Osório FL, Sanches R, Dos Santos RG, et al. 2019. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 49:655–663.
   PubMed Web of Science ®Google Scholar
• Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A, De Sarro G, Gallelli L. 2013. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 18(7):601–610.
   PubMed Web of Science ®Google Scholar
• Pantano F, Tittarelli R, Mannocchi G, Zaami S, Ricci S, Giorgetti R, Terranova D, Busardò F, Marinelli E. 2016. Hepatotoxicity Induced by “the 3Ks”: Kava, Kratom and Khat. IJMS. 17(4):580.
   Web of Science ®Google Scholar
• Pasanen M, Pellinen P, Stenbäck F, Juvonen RO, Raunio H, Pelkonen O. 1995. The role of CYP enzymes in cocaine-induced liver damage. Arch Toxicol. 69(5):287–290.
   PubMed Web of Science ®Google Scholar
• Pastor A, Conn J, Teng J, O'Brien CL, Loh M, Collins L, MacIsaac R, Bonomo Y. 2017. Alcohol and recreational drug use in young adults with type 1 diabetes. Diabetes Res Clin Pract. 130:186–195.
   PubMed Web of Science ®Google Scholar
• Pedersen AJ, Reitzel LA, Johansen SS, Linnet K. 2013. In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Test Anal. 5(6):430–438.
   PubMed Web of Science ®Google Scholar
• Pellinen P, Stenback F, Kojo A, Honkakoski P, Gelboin HV, Pasanen M. 1996. Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology. 23(3):515–523.
   PubMed Web of Science ®Google Scholar
• Petzinger E, Geyer J. 2006. Drug transporters in pharmacokinetics. Naunyn Schmied Arch Pharmacol. 372(6):465–475.
   PubMed Web of Science ®Google Scholar
• Pilgrim JL, Gerostamoulos D, Drummer OH. 2011. Deaths involving MDMA and the concomitant use of pharmaceutical drugs. J Anal Toxicol. 35(4):219–226.
   PubMed Web of Science ®Google Scholar
• Pilgrim JL, Gerostamoulos D, Woodford N, Drummer OH. 2012. Serotonin toxicity involving MDMA (ecstasy) and moclobemide. Forensic Sci Int. 215(1–3):184–188.
   PubMed Web of Science ®Google Scholar
• Piper BJ, DeKeuster RM, Beals ML, Cobb CM, Burchman CA, Perkinson L, Lynn ST, Nichols SD, Abess AT. 2017. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol. 31(5):569–575.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. 1998. Adverse drug reactions. BMJ. 316(7140):1295–1298.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. 2004. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 329(7456):15–19.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Elliot DJ, Somogyi AA, Gillam EMJ, Lewis BC, Miners JO. 2006. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 61(5):570–584.
   PubMed Web of Science ®Google Scholar
• Pondugula S R, Flannery P C, Abbott K L, Coleman E S, Mani S, Samuel T, Xie W. 2015a. Diindolylmethane, a naturally occurring compound, induces CYP3A4 and MDR1 gene expression by activating human PXR. Toxicol Lett. 232(3):580–589.
   PubMed Web of Science ®Google Scholar
• Pondugula S R, Flannery P C, Apte U, Babu J R, Geetha T, Rege S D, Chen T, Abbott K L. 2015b. Mg2+/Mn2+-dependent phosphatase 1A is involved in regulating pregnane X receptor-mediated cytochrome p450 3A4 gene expression. Drug Metab Dispos. 43(3):385–391.
   PubMed Web of Science ®Google Scholar
• Pondugula SR, Mani S. 2013. Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response [Research Support, N.I.H., Extramural Review]. Cancer Lett. 328(1):1–9.
   PubMed Web of Science ®Google Scholar
• Pondugula SR, Pavek P, Mani S. 2016. Pregnane X receptor and cancer: context-specificity is key. Nucl Receptor Res. 3: 101198. DOI:10.11131/2016/101198.
   PubMedGoogle Scholar
• Projean D, Morin P-E, Tu TM, Ducharme J. 2003. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica. 33(8):841–854.
   PubMed Web of Science ®Google Scholar
• Prosser JM, Nelson LS. 2012. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 8(1):33–42.
   PubMedGoogle Scholar
• Prozialeck WC, Jivan JK, Andurkar SV. 2012. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 112(12):792–799.
   PubMedGoogle Scholar
• Riba J, McIlhenny EH, Bouso JC, Barker SA. 2015. Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study. Drug Test Anal. 7(5):401–406.
   PubMed Web of Science ®Google Scholar
• Riba J, McIlhenny EH, Valle M, Bouso JC, Barker SA. 2012. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca. Drug Test Anal. 4(7–8):610–616.
   PubMed Web of Science ®Google Scholar
• Rieder MJ. 1994. Mechanisms of unpredictable adverse drug reactions. Drug Saf. 11(3):196–212.
   PubMed Web of Science ®Google Scholar
• Riedl MA, Casillas AM. 2003. Adverse drug reactions: types and treatment options. Am Fam Physician. 68(9):1781–1790.
   PubMed Web of Science ®Google Scholar
• Rodvelt KR, Miller DK. 2010. Could sigma receptor ligands be a treatment for methamphetamine addiction? Curr Drug Abuse Rev. 3(3):156–162.
   PubMedGoogle Scholar
• Roldan CJ. 2014. Phenytoin toxicity from cocaine adulteration. WestJEM. 15(2):127–130.
   Google Scholar
• Romanelli F, Smith KM, Pomeroy C. 2003. Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men. Top HIV Med. 11(1):25–32.
   PubMedGoogle Scholar
• Rosenberg AR, Bona K, Ketterl T, Wharton CM, Wolfe J, Baker KS. 2017. Intimacy, substance use, and communication needs during cancer therapy: a report from the “resilience in adolescents and young adults” study. J Adolesc Health. 60(1):93–99.
   PubMed Web of Science ®Google Scholar
• Royer RJ. 1997. Mechanism of action of adverse drug reactions: an overview. Pharmacoepidemiol Drug Saf. 6(S3):S43–S50.
   PubMed Web of Science ®Google Scholar
• Rusli N, Amanah A, Kaur G, Adenan MI, Sulaiman SF, Wahab HA, Tan ML. 2019. The inhibitory effects of mitragynine on P-glycoprotein in vitro. Naunyn Schmiedebergs Arch Pharmacol. 392(4):481–496.
   PubMed Web of Science ®Google Scholar
• Russo EB, Guy GW, Robson PJ. 2007. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. C&B. 4(8):1729–1743.
   Web of Science ®Google Scholar
• Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N. 2014. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther. 95(6):653–662.
   PubMed Web of Science ®Google Scholar
• SAMHSA. 2019. National Survey on Drug use and Health. Rockville (MD): SAMHSA. https://nsduhweb.rti.org/.
   Google Scholar
• Schindler CW, Thorndike EB, Blough BE, Tella SR, Goldberg SR, Baumann MH. 2014. Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats. Br J Pharmacol. 171(1):83–91.
   PubMed Web of Science ®Google Scholar
• Schmid Y, Rickli A, Schaffner A, Duthaler U, Grouzmann E, Hysek CM, Liechti ME. 2015. Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. J Pharmacol Exp Ther. 353(1):102–111.
   PubMed Web of Science ®Google Scholar
• Schmidt MS, Prisinzano TE, Tidgewell K, Harding W, Butelman ER, Kreek MJ, Murry DJ. 2005. Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci. 818(2):221–225.
   PubMed Web of Science ®Google Scholar
• Serra V, Fattore L, Scherma M, Collu R, Spano MS, Fratta W, Fadda P. 2015. Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat. Psychopharmacology (Berl). 232(1):91–100.
   PubMed Web of Science ®Google Scholar
• Sessa B. 2017. MDMA and PTSD treatment: “PTSD: from novel pathophysiology to innovative therapeutics”. Neurosci Lett. 649:176–180.
   PubMed Web of Science ®Google Scholar
• Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B, Li C. 2007. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos. 35(8):1292–1300.
   PubMed Web of Science ®Google Scholar
• Shimomura ET, Briones AJ, Warren WS, Addison JW, Knittel JL, Shoemaker SA, King TD, Bosy TZ. 2016. Case report of methylone, oxymorphone and ethanol in a fatality case with tissue distribution. J Anal Toxicol. 40(7):543–545.
   PubMed Web of Science ®Google Scholar
• Simmler LD, Anacker AMJ, Levin MH, Vaswani NM, Gresch PJ, Nackenoff AG, Anastasio NC, Stutz SJ, Cunningham KA, Wang J, et al. 2017. Blockade of the 5-HT transporter contributes to the behavioural, neuronal and molecular effects of cocaine. Br J Pharmacol. 174(16):2716–2738.
   PubMed Web of Science ®Google Scholar
• Simmons SJ, Leyrer-Jackson JM, Oliver CF, Hicks C, Muschamp JW, Rawls SM, Olive MF. 2018. DARK classics in chemical neuroscience: cathinone-derived psychostimulants. ACS Chem Neurosci. 9(10):2379–2394.
   PubMed Web of Science ®Google Scholar
• Smilkstein MJ, Smolinske SC, Rumack BH. 1987. A case of MAO inhibitor/MDMA interaction: agony after ecstasy. J Toxicol Clin Toxicol. 25(1-2):149–159.
   PubMed Web of Science ®Google Scholar
• Somala RK. 2009. Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male. Invited comment. Acta Psychiatr Scand. 120(1):80–81.
   PubMed Web of Science ®Google Scholar
• Staudinger JL. 2013. Disease, drug metabolism, and transporter interactions. Pharm Res. 30(9):2171–2173.
   PubMed Web of Science ®Google Scholar
• Stone DM, Stahl DC, Hanson GR, Gibb JW. 1986. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol. 128(1–2):41–48.
   PubMed Web of Science ®Google Scholar
• Stott C, White L, Wright S, Wilbraham D, Guy G. 2013. A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. Springerplus. 2(1):236.
   PubMedGoogle Scholar
• Stout SM, Cimino NM. 2014. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 46(1):86–95.
   PubMed Web of Science ®Google Scholar
• Swogger MT, Walsh Z. 2018. Kratom use and mental health: a systematic review. Drug Alcohol Depend. 183:134–140.
   PubMed Web of Science ®Google Scholar
• Teksin ZS, Lee IJ, Nemieboka NN, Othman AA, Upreti VV, Hassan HE, Syed SS, Prisinzano TE, Eddington ND. 2009. Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 72(2):471–477.
   PubMed Web of Science ®Google Scholar
• Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, Sukasem C, Wananukul W. 2015. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther. 9:2421–2429.
   PubMed Web of Science ®Google Scholar
• Troost J, Tatami S, Tsuda Y, Mattheus M, Mehlburger L, Wein M, Michel MC. 2011. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol. 72(2):247–256.
   PubMed Web of Science ®Google Scholar
• Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H. 2009. In vitro stability and metabolism of salvinorin A in rat plasma. Xenobiotica. 39(5):391–398.
   PubMed Web of Science ®Google Scholar
• Turri M, Teatini F, Donato F, Zanette G, Tugnoli V, Deotto L, Bonetti B, Squintani G. 2018. Pain modulation after oromucosal cannabinoid spray (SATIVEX((R))) in patients with multiple sclerosis: a study with quantitative sensory testing and laser-evoked potentials. Medicines (Basel). 5(3):59.
   PubMedGoogle Scholar
• Vizeli P, Liechti ME. 2017. Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol. 31(5):576–588.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. 1998. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 9(17):3897–3902.
   PubMed Web of Science ®Google Scholar
• Vuori E, Henry JA, Ojanperä I, Nieminen R, Savolainen T, Wahlsten P, Jäntti M. 2003. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction. 98(3):365–368.
   PubMed Web of Science ®Google Scholar
• Wagmann L, Meyer MR, Maurer HH. 2016. What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? Toxicol Lett. 258:55–70.
   PubMed Web of Science ®Google Scholar
• Wagmann L, Richter LHJ, Kehl T, Wack F, Bergstrand MP, Brandt SD, Stratford A, Maurer HH, Meyer MR. 2019. In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Anal Bioanal Chem. 411(19):4751–4763.
   PubMed Web of Science ®Google Scholar
• Wagner DJ, Duan H, Chapron A, Lee RW, Wang J. 2017. Potent inhibition of human organic cation transporter 2 (hOCT2) by beta-carboline alkaloids. Xenobiotica. 47(12):1112–1120.
   PubMed Web of Science ®Google Scholar
• White CM. 2016. Mephedrone and 3,4-methylenedioxypyrovalerone (MDPV): synthetic cathinones with serious health implications. J Clin Pharmacol. 56(11):1319–1325.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 1972. International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Organ Tech Rep Ser. 498:1–25.
   PubMedGoogle Scholar
• Wu J-J, Ai C-Z, Liu Y, Zhang Y-Y, Jiang M, Fan X-R, Lv A-P, Yang L. 2012. Interactions between phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes. CDM. 13(5):599–614.
   Web of Science ®Google Scholar
• Wu L-T, Ghitza UE, Zhu H, Spratt S, Swartz M, Mannelli P. 2018. Substance use disorders and medical comorbidities among high-need, high-risk patients with diabetes. Drug Alcohol Depend. 186:86–93.
   PubMed Web of Science ®Google Scholar
• Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K. 2011. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 88(15–16):730–736.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shimada T. 1998. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 26(11):1053–1057.
   PubMed Web of Science ®Google Scholar
• Yamreudeewong W, Wong HK, Brausch LM, Pulley KR. 2009. Probable interaction between warfarin and marijuana smoking. Ann Pharmacother. 43(7–8):1347–1353.
   PubMed Web of Science ®Google Scholar
• Yu A-M, Idle JR, Krausz KW, Küpfer A, Gonzalez FJ. 2003. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther. 305(1):315–322.
   PubMed Web of Science ®Google Scholar
• Zendulka O, Dovrtělová G, Nosková K, Turjap M, Šulcová A, Hanuš L, Juřica J. 2016. Cannabinoids and cytochrome P450 interactions. CDM. 17(3):206–226.
   Web of Science ®Google Scholar
• Zhang L, Zhang Y, Zhao P, Huang S-M. 2009. Predicting drug-drug interactions: an FDA perspective. AAPS J. 11(2):300–306.
   PubMed Web of Science ®Google Scholar
• Zhao T, He Y-Q, Wang J, Ding K-M, Wang C-h, Wang Z-T. 2011. Inhibition of human cytochrome P450 enzymes 3A4 and 2D6 by beta-carboline alkaloids, harmine derivatives. Phytother Res. 25(11):1671–1677.
   PubMed Web of Science ®Google Scholar
• Zimmerman JL. 2012. Cocaine intoxication. Crit Care Clin. 28(4):517–526.
   PubMed Web of Science ®Google Scholar